< Zurück zu den aktuellen Neuigkeiten & Events

Articles

The end of the UPC as we know it?

März 2020

The German Federal Constitutional Court has issued a decision (in German) which ruled the German UPCA Ratification Law to be unconstitutional and void.  However, the court dismissed the second set of arguments (violation of fundamental democratic rights and the principle of separation of powers) as inadmissible.

So while a significant blow to progress of the UPC, it is possible that the UPC bill could be presented once more to the Bundestag, where the present Government might be able to get the required two-thirds majority.  Of course, this will take a while to be tabled in view of the present global COVID-19 crisis and also raises the possibility of whether the same complaint could be brought again but focussed on more substantive aspects like transfer of sovereign rights, issues with the EPO, judges, to name but a few.  Furthermore, given that the UK has indicated it will no longer seek to participate in unitary patent and UPC, the agreement in its current form would need significant amendment before it could again be taken through the German constitutional process.

The UPC prep committee has commented that “Despite the fact that the judgement will result in further delay the preparatory work will continue, while the judgment and the way forward is further analysed”.  Less surprisingly, they also stated that “It should be acknowledged that all colleagues working for the Preparatory Committee are facing unprecedented challenges with the COVID-19 outbreak but work will move forward using all available resources to keep the momentum”.

This update was prepared by HGF Partner Rachel Fetches.  If you would like further advice on this or any other matter, please contact Rachel. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen